Life-sciences companies faced fewer class-action securities lawsuits last year, continuing a trend of declining litigation over the last few years, according to a report published in February by the law firm Dechert LLP.Investors filed…
Continue Reading
As a health economist, researcher in evidence-based medicine, and consultant to biopharma executives, I am no stranger to data. We all want more of it, to make sense of it, and to use it…
Continue Reading
More and more healthcare leaders are beginning to treat violence as a public health issue as gun deaths and other forms of assault continue to impact communities across the country. One large health system…
Continue Reading
Eli Lilly is cutting insulin prices, and this time it’s for real.
Months after a Twitter account posing as the drugmaker went viral with a tweet stating, “insulin is free now,” the company on Wednesday…
Nearly one in five people who are incarcerated battle opioid use disorder (OUD), and opioid-related overdose is the leading cause of death for those released from the criminal justice system. A new collaboration aims…
Continue Reading
I practiced cardiology in North Carolina for nearly 15 years. Many of my patients lived in rural, underserved communities. The effectiveness of my clinical practice was largely informed by my ability to reach my…
Continue Reading
I’m headed to several conferences over the next two months. I spent some time this weekend going through the agendas and looking at the details to identify specific sessions I’d like to attend.
Smaller…
Safety is paramount in medical care, rooted in the most basic tenet of medicine: First, do no harm. But, although acute medical care presents myriad risks to patient safety, there is no category for…
Continue Reading
Cough, fever, and breathing difficulty could signal a Covid-19 infection. It could also be the flu. A Lucira Health diagnostic is now the first one authorized by the FDA to identify the culprit virus…
Continue Reading
A Fulcrum Therapeutics clinical trial testing a potential sickle cell disease drug has been paused by the FDA. With the clinical hold on the early-stage study, Fulcrum becomes the fourth company with a stalled…
Continue Reading
